U.S. FDA approves ScPharmaceuticals' heart failure therapy
10/10/2022 13:05
Oct 10 (Reuters) - The U.S. Food and Drug Administration
on Monday approved ScPharmaceuticals Inc's SCPH.O therapy for
patients with chronic heart failure.
The approval marks the end of a long path to the market for
the therapy, Furoscix, after the regulator rejected it twice in
the past.
The drug is delivered via an on-body infusor. Heart failure
is a long-term condition in which the heart cannot pump enough
blood to meet the body's needs all the time.
(Reporting by Manas Mishra in Bengaluru; Editing by Arun
Koyyur)
((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15;))